Drug Pipeline Series: Submissions, Dec 4 - Dec 11, 2006

Theravance, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for telavancin, a rapidly bactericidal injectable antibiotic with a unique multifunctional mechanism of action, for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.

Eli Lilly and Company announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration's Division of Drug Oncology Products (DDOP) for EVISTA® (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer. EVISTA is currently indicated for the treatment and prevention of osteoporosis in postmenopausal women.